^
Association details:
| Biomarker: | CRY1 rs1056560 |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Stivarga (regorafenib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
465P - Single nucleotide polymorphism (SNP) analysis identifies potential prognostic and predictive biomarker in patients (pts) with metastatic colorectal cancer (mCRC) treated with regorafenib in the phase III CORRECT trial
Published date:
09/14/2020
Excerpt:
A functional SNP, rs1056560, in the CRY1 gene in the clock pathway was significantly associated with OS (P < .001, Q = .06)….the first time we identify a potential predictive biomarker for regorafenib in the CORRECT population….Our finding helps better understand regorafenib response and may support alternative treatment choices based on CRY1 rs1056560 genotypes to optimize regorafenib benefit.
Trial ID:
